Compare Manchester United PLC (MANU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs ResMed Inc. — how do they compare? Manchester United PLC trades at $22.38 (market cap $3.80B), while ResMed Inc. trades at $195.68 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 7.6× Manchester United PLC's market cap, and Manchester United PLC pays the higher dividend (1.26%). Which is the better fit depends on your goals.
| MANU | RMD | |
|---|---|---|
Market Cap | $3.80B | $28.81B |
Sector | Media | Health |
52-Week High | $23.53 | $293.73 |
52-Week Low | $15.10 | $182.82 |
Enterprise Value | $4.72B | $27.99B |
Dividend Yield | 1.26% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.05, down 0.81% today, with a bullish technical signal from moving averages but mixed recent earnings performance. Revenue grew to $667M in 2025, yet net losses persist at -$33M. The company is advancing a new 100,000-seat stadium project, a key long-term growth driver, while securing Champions League qualification boosts future revenue prospects.
Outlook hinges on stadium development execution and sustained sporting success to drive profitability. Risks include high debt levels and inconsistent earnings. Analysts are cautiously optimistic with 40% buy ratings, but investors should monitor cash flow trends amid significant capital expenditures.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
